Park Hotels & Resorts Announces Fourth Quarter and Full Year 2023 Earnings Conference Call on February 28, 2024
TYSONS, Va., Jan. 05, 2024 (GLOBE NEWSWIRE) — Park Hotels & Resorts Inc. (NYSE: PK) (“Park”) today announced that it […]
Matthews International Announces First Quarter Fiscal 2024 Earnings Release and Conference Call
PITTSBURGH, Jan. 05, 2024 (GLOBE NEWSWIRE) — Matthews International Corporation (Nasdaq GSM: MATW) today announced plans to release its first […]
ECARX Announces Board Changes
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech […]
Grupo Aeroportuario del Pacifico Reports in December 2023 a Passenger Traffic Increase of 2.2% Compared to 2022
GUADALAJARA, Mexico, Jan. 05, 2024 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the […]
Semantix Provides Update Regarding Nasdaq Minimum Bid Price Compliance
SÃO PAULO, Brazil, Jan. 05, 2024 (GLOBE NEWSWIRE) — Semantix, Inc. (NASDAQ: STIX), a leading Latin American enterprise AI platform […]
Triumph Financial Announces Schedule for Fourth Quarter 2023 Earnings Release and Conference Call
DALLAS, Jan. 05, 2024 (GLOBE NEWSWIRE) — Triumph Financial, Inc. (Nasdaq: TFIN) today announced that it expects to release its […]
Societal CDMO Reports Inducement Grants for New Staff
SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract […]
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering […]
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from […]
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics […]
